[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tel-Aviv Sourasky Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":672},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,33,0,25,[9,44,67,92,118,146,170,195,217,245,267,294,329,375,400,426,446,471,493,521,558,580,600,628,647],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644308","tele-pulmonary-rehabilitation-for-copd-patients-living-in-peripheral-areas-100644308",false,"NCT07666854","Tele-Pulmonary Rehabilitation For COPD Patients Living in Peripheral Areas","Examining the Feasibility and Effectiveness of a Remote Group Respiratory Rehabilitation Program for Patients With Chronic Obstructive Pulmonary Disease Living in Peripheral Areas as a First Step to Policy Change","TELE-PR-PRPRL","Inclusion Criteria:\n\n* Male and females Patients with COPD based on accepted criteria who are eligible for reimbursement of pulmonary rehabilitation (PR) according to the Israeli \"health basket\" criteria including one of the following:\n\n  * FEV1 below 50%\n  * Severe exacerbation (hospitalization) in the previous year\n  * Two moderate exacerbations in the previous year\n* Willingness to initiate a PR or TPR programs.\n* Living in geographic peripheral area.\n* Ability to perform the TPR program or traditional PR activities as assessed by a member of the study team prior to enrollment.\n* Agree to participate, with signed informed consent.\n* Age \\> 18.\n\nExclusion Criteria:\n\n* Uncontrolled comorbidity (e.g uncontrolled congestive heart failure).\n* Inability to operate the mobile application.\n* Without a mobile device or computer.\n* An exacerbation in the 2-months prior to randomization.\n* Completed PR program in the last 12 months.\n* Pregnancy.\n* Patients with cognitive impairment.","ALL","40 Years",{"count":21,"type":22},110,"ESTIMATED","INTERVENTIONAL",[25],"NA","Pulmonary rehabilitation (PR) is a key non-pharmacological intervention for patients with chronic obstructive pulmonary disease (COPD), yet it remains underutilized, particularly among patients living in peripheral areas due to limited access, travel distance, and logistical barriers. Tele-pulmonary rehabilitation (TPR) has the potential to improve access to care, but its feasibility and effectiveness as a group-based intervention have not been well established.\n\nThe aim of this study is to evaluate whether a group-based TPR program can improve treatment initiation and adherence compared to usual care, defined as referral to standard PR, among COPD patients living in peripheral areas. In addition, the study will assess the effect of the intervention on COPD exacerbations, symptom burden, quality of life, and patient satisfaction.\n\nThis is a prospective randomized controlled trial that will enroll patients with COPD who are eligible for PR according to the Israeli health basket criteria and have not participated in PR in the past year. Participants will be randomly assigned to one of two groups: (1) referral to standard PR (control group), or (2) participation in a 12-week, twice-weekly, group-based TPR program delivered remotely via a dedicated application and video sessions (intervention group).",[28,29,30],"COPD (Chronic Obstructive Pulmonary Disease)","Rehabilitation","Peripheral","NOT_YET_RECRUITING","2026-06-18",{"date":34,"type":35},"2026-06-24","ACTUAL",{"date":37,"type":22},"2026-07-01",{"date":39,"type":22},"2028-08-01",{"name":41,"class":42},"Tel-Aviv Sourasky Medical Center","OTHER_GOV",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100644283","tele-pulmonary-rehabilitation-for-patients-with-chronic-lung-diseases-100644283","NCT07666841","Tele-Pulmonary Rehabilitation For Patients With Chronic Lung Diseases","Tele-Pulmonary Rehabilitation to Improve Adherence and Management of Patients With Chronic Lung Diseases","TELE-PRIME","Inclusion Criteria:\n\n1. Patients meeting the Israeli Health Basket criteria for reimbursement of pulmonary rehabilitation (PR), including one of the following conditions:\n\n   * COPD with an FEV1 below 50% or with severe exacerbation (hospitalization) in the previous year or two moderate exacerbations in the previous year.\n   * Interstitial lung disease with an FVC below 80% or a DLCO below 60%.\n   * Bronchiectasis with at least two exacerbations in the past year or at least one hospitalization, and an FEV1 below 80%.\n   * Pulmonary arterial hypertension.\n2. Willingness to initiate a PR or Tele-PR (TPR) programs.\n3. Ability to perform the TPR program or traditional PR activities as assessed by a member of the study team prior to enrollment.\n4. Agree to participate, with signed informed consent.\n\nExclusion Criteria:\n\n1. Uncontrolled comorbidity (e.g uncontrolled congestive heart failure)\n2. Inability to operate the mobile application.\n3. Without a mobile device or computer.\n4. A hospitalization in the 2-months prior to randomization.\n5. Completed PR program in the last 12 months.\n6. Inability to complete 10 repetitions in the 1-minute sit-to-stand test or 5-second single-leg stance\n7. Pregnancy\n8. Inability to provide informed consent due to impaired decision-making capacity, as determined by the study's capacity assessment.","18 Years",{"count":54,"type":22},90,[25],"Pulmonary rehabilitation is a key treatment for lung diseases, but many patients struggle to attend sessions due to travel distances, physical limitations, or logistical barriers. The purpose of this study is to evaluate whether a tele-pulmonary rehabilitation (TPR) program can improve the rates of treatment initiation and adherence among patients with chronic lung diseases compared to traditional, center-based pulmonary rehabilitation. Additionally, the study will assess improvements in quality of life, physical symptoms, and safety in both groups.\n\nThis study will enroll 90 patients from two medical centers in Israel (Tel Aviv and Barzilai). Participants will be randomly assigned to one of two groups:\n\n1. The control group will receive usual care with a referral by a pulmonologist to standard pulmonary rehabilitation at a medical center.\n2. The intervention group will participate in a supervised remote tele-rehabilitation program using a dedicated application and remote monitoring.",[28,29,58,59,60],"Bronchiectasis Adult","Pulmonary Arterial Hypertension (PAH)","Interstitial Lung Disease (ILD)",{"date":34,"type":35},{"date":37,"type":22},{"date":64,"type":22},"2028-12-31",{"name":41,"class":42},2,{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":91,"locationsCount":43},"100639765","copd-flare-up-clinic-after-severe-exacerbations-100639765","NCT07629869","COPD Flare-Up Clinic After Severe Exacerbations","The Role of COPD Flare-up Clinic Service After Severe Exacerbations to Reduce Recurrent Exacerbations","FLARE-COPD","Inclusion Criteria:\n\n* Prior COPD diagnosis based on clinical and spirometry accepted criteria.\n* Acute exacerbation of COPD as the main reason for ED arrival.\n* Ability to perform in-person and telephone follow-up.\n* Agree to participate, with a signed informed consent.\n\nExclusion Criteria:\n\n* Symptomatic heart failure as the main reason for emergency department visit in the last 6 months.\n* Uncontrolled comorbidity.\n* Vulnerable Populations: To ensure ethical compliance and participant safety, the study will exclude vulnerable populations. This includes pregnant women, and any person lacking the mental or legal capacity to provide independent informed consent.","80 Years",{"count":77,"type":22},240,[25],"This prospective randomized controlled trial evaluates whether a specialized \"COPD flare-up clinic service\" improves outcomes in patients following an acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Patients presenting to the emergency department with AECOPD and discharged or hospitalized will be randomized 1:1 to either structured follow-up in a dedicated flare-up clinic or standard follow-up by scheduled telephone interviews.\n\nThe researches hypothesize that structured follow-up in a specialized clinic will reduce recurrent exacerbations, optimize long-term COPD management, and improve patients' quality of life compared to standard care.",[81,82],"COPD","COPD Exacerbation (AECOPD)",[84,85,86],"COPD management","COPD flare-up","COPD exacerbation",{"date":88,"type":35},"2026-06-23",{"date":37,"type":22},{"date":64,"type":22},{"name":41,"class":42},{"id":93,"slug":94,"hasResults":12,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":104,"conditions":105,"keywords":108,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":116,"leadSponsor":117,"locationsCount":43},"100641326","post-exacerbation-asthma-clinic-telecare-intervention-to-reduce-recurrent-exacerbations-100641326","NCT07629830","Post Exacerbation Asthma Clinic Telecare Intervention to Reduce Recurrent Exacerbations","A Remote Clinic Intervention Following Hospital Discharge for Asthma Exacerbation to Reduce Recurrent Exacerbations","PACT","Inclusion Criteria:\n\n* Presentation to the emergency department with an asthma exacerbation.\n* Ability to complete telephone follow-up and access to a personal e-mail account.\n* Agreement to participate in the study.\n* Written or verbal informed consent according to study group assignment.\n\nExclusion Criteria:\n\n* Uncontrolled cardiac disease.\n* Any other uncontrolled medical condition.\n* Inability to complete telephone follow-up.\n* Pregnancy.\n* Patients lacking decision-making capacity.","75 Years",{"count":102,"type":22},220,[25],"Asthma exacerbations leading to emergency department visits or hospitalization are associated with a high risk of recurrent exacerbations, poor disease control, and increased healthcare utilization in the months following discharge. Early specialist follow-up during this vulnerable transition period remains limited, and many patients do not receive optimized long-term asthma management. The purpose of this study is to evaluate whether a structured remote asthma clinic intervention initiated shortly after hospital discharge can reduce recurrent exacerbations and improve asthma-related outcomes compared to standard community care.\n\nThis prospective randomized study will enroll 220 adult patients (18-75 years) presenting to the emergency department at Tel Aviv Sourasky Medical Center with an asthma exacerbation. Participants will be randomly assigned to one of two groups:\n\n1. Intervention group - will undergo two structured remote pulmonology follow-up visits via secure video consultation within 7-21 days and 5 months after discharge, including treatment optimization, inhaler technique assessment, and self-management education.\n2. Control group - will continue standard community care without additional intervention.\n\nAll participants will complete scheduled follow-up assessments over 12 months, including evaluation of exacerbations, asthma control, healthcare utilization, and medication use.",[106,107],"Asthma Acute","Asthma Attack",[109,110,111,112],"Asthma flare-up","Asthma management","remote clinic","pulmonologist",{"date":114,"type":35},"2026-06-22",{"date":37,"type":22},{"date":64,"type":22},{"name":41,"class":42},{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":12,"sex":18,"minAge":126,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":43},"100642562","everst--everolimus-after-alpelisib-in-women-with-hormone-receptor-positive-hr-metastatic-breast-cancer-mbc-100642562","NCT07646171","EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)","EVERST- Everolimus After Alpelisib in Women With HR+ MBC- This Phase II, Open-label, Single-arm, Study Investigates the Clinical Benefit of Everolimus Combined With Endocrine Therapy. in Hormone Receptor-positive (HR+), Metastatic Breast Cancer Patients Who Progressed on Prior PI3K Inhibitor Therapy With Endocrine Therapy. The Trial Aims to Determine if Sequential Inhibition of the PI3K\u002FAKT\u002FmTORC1 Pathway Retains Efficacy Post-PI3K Inhibitor Resistance, Hypothesizing That Everolimus Will Demonstrate a Response Rate Exceeding the Historical 9.5% Observed in the BOLERO2 Trial.","MBC","Inclusion Criteria:\n\n* HR+MBC with PI3Kmut Post CDK 4\u002F6+ET Post PI3K inhibitor+ET\n\nExclusion Criteria:\n\n* Women who didn't receive anti-PI3K","21 Years",{"count":128,"type":22},19,"OBSERVATIONAL","This phase II, open-label, single-arm, study investigates the clinical benefit of everolimus combined with endocrine therapy (ET) in hormone receptor-positive (HR+), metastatic breast cancer (MBC) patients who progressed on prior PI3K inhibitor therapy (+ ET). The trial aims to determine if sequential inhibition of the PI3K\u002FAKT\u002FmTORC1 pathway retains efficacy post-PI3K inhibitor resistance, hypothesizing that everolimus will demonstrate a response rate exceeding the historical 9.5% observed in the BOLERO2 trial.",[132],"Hormone Receptor Positive Breast Cancer",[134,135,136],"mTOR inhibitor","Hormone receptor positive breast cancer","PI3K inhibitor","RECRUITING","2026-06-09",{"date":140,"type":35},"2026-06-12",{"date":142,"type":35},"2022-09-01",{"date":144,"type":22},"2027-12-31",{"name":41,"class":42},{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":23,"phases":155,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":43},"100620715","phase-1-investigator-initiated-study-to-assess-the-safety-of-combination-of-cls-015-with-anti-cd-19-car-t-cells-in-patients-with-stableprogressive-large-b-cell-lymphoma-at-lymphodepletion-100620715","NCT07361224","Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable\u002FProgressive Large B Cell Lymphoma at Lymphodepletion.","CLS-015-TAMSC-LBCL-PR An Exploratory, Investigator Initiated Study to Assess the Safety of Combination of CLS-015 (DFF) With Anti-CD-19 CAR-T Cells in Patients With Stable\u002F Progressive Large B Cell Lymphoma at Lymphodepletion.","Inclusion Criteria:\n\n* Participant must be at least 18 years of age inclusive, at the time of signing the informed consent.\n* Large B-Cell lymphoma treated with CAR-T targeting CD19 (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel)\n* Stable Disease or Progressive Disease confirmed by PET-CT on the day of lymphodepletion\n* Capable of giving signed informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n\nExclusion Criteria:\n\n* Hypersensitivity to CLS-015\n* Evidence of any clinically significant condition, disorder, condition, or disease that, in the opinion of the Investigator would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.\n* Active infection requiring antibiotics\n* Females only: Pregnant or breastfeeding",{"count":154,"type":22},12,[156],"PHASE1","This is a Phase 1, single-center, open-label study to evaluate the safety of CLS-015 in combination with anti-CD19 CAR-T therapy in patients with large B-cell lymphoma. The goal is to improve clinical response by reversing the negative effects of NETs on immune function and CAR-T cells.",[159],"Large B-Cell Lymphoma (LBCL)",[161],"Large B-Cell lymphoma","2026-04-27",{"date":164,"type":35},"2026-05-01",{"date":166,"type":22},"2026-05",{"date":168,"type":22},"2028-02",{"name":41,"class":42},{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":23,"phases":179,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":43},"100622216","feasibility-and-preliminary-effects-of-the-walking-tall-app-for-home-based-gait-training-in-parkinsons-disease-a-pilot-study-100622216","NCT07380737","Feasibility and Preliminary Effects of the Walking Tall App for Home-Based Gait Training in Parkinson's Disease: A Pilot Study","Inclusion Criteria:\n\n* Clinical diagnosis of idiopathic Parkinson's disease (MDS criteria);\n* Hoehn \\& Yahr stage II-III (ON-medication state);\n* Able to walk independently for ≥5 minutes;\n* Stable medication for ≥1 month;\n* Currently enrolled in a rehab program at Ezra LeMarpe;\n* Able to provide written informed consent;\n\nExclusion Criteria:\n\n* Musculoskeletal, neurological, or visual\u002Fhearing impairments affecting gait;\n* Cognitive impairments or severe behavioral symptoms;\n* History of stroke, severe TBI, or brain tumor;\n* Cardiovascular contraindications;\n* Inability to use a smartphone;\n* Participation in other concurrent intervention studies.","85 Years",{"count":178,"type":22},30,[25],"This is a pilot study designed to assess the feasibility, adherence, and preliminary effects of a 6-week home-based gait training intervention using the Walking Tall mobile app in individuals with Parkinson's disease. The app delivers rhythmic auditory cues and motivational verbal prompts to promote gait improvements. Primary outcomes include daily walking duration and step count measured via wearable sensors; secondary outcomes include gait speed, balance, self-reported confidence, and usability.",[182],"Parkinson's Disease",[184,182,185,186],"Gait","Walking App","Rhythmic auditory cueing","2026-02-12",{"date":189,"type":35},"2026-02-13",{"date":191,"type":35},"2025-12-29",{"date":193,"type":22},"2026-12-31",{"name":41,"class":42},{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":201,"sex":18,"minAge":202,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":216},"100503640","predicting-progression-of-developing-myeloma-in-a-high-risk-screened-population-and-general-population-100503640","NCT05837884","Predicting Progression of Developing Myeloma in a High-Risk Screened Population and General Population","Inclusion Criteria:\n\n* Must meet criteria of the high-risk population as described with one of the below criteria\n\n  * ≥ 30 years AND\n  * first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer.\n\nOR\n\n* Age ≥ 18 years with 2 or more first- or second-degree relatives with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer '\n* Voluntary written informed consent must be given with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care\n\nExclusion Criteria:\n\n* • Persons diagnosed with cancer at any site (including hematologic cancers) with symptomatic disease requiring active therapy.\n\n  * Persons with an already diagnosed plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia\n  * Female patient who have a positive serum pregnancy test during the screening period or a positive pregnancy test.",true,"30 Years",{"count":204,"type":22},2000,"We will seek consent from participants to use the data and biospecimens collected according study protocol to address additional research questions for MGUS, SMM, MM, and other conditions.\n\nOur overarching hypothesis is that early detection of MGUS\u002FSMM in a high- risk population, along with the comprehensive characterization of genomic\u002Fepigenomic and microenvironmental\u002Fimmune regulators of disease progression will lead to strategies that intercept disease progression and improve survival.",[207],"Healthy","2026-02-01",{"date":210,"type":35},"2026-02-04",{"date":212,"type":35},"2023-09-05",{"date":214,"type":22},"2028-06",{"name":41,"class":42},3,{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":23,"phases":227,"briefSummary":229,"conditions":230,"keywords":233,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":66},"100618084","phase-2-mri-guided-neoadjuvant-treatment-de-escalation-in-stage-ii-iii-tnbc-100618084","NCT07327021","MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC","NOGA: Neoadjuvant Treatment Optimization Via MRI-Guided De-Escalation in Stage II-III TNBC - A Phase 2 Study.","NOGA","Inclusion Criteria:\n\n* Patient is eligible per physician's discretion for the KEYNOTE-522 regimen (Neoadjuvant paclitaxel-carboplatin-doxorubicin-cyclophosphamide-pembrolizumab)\n* Signed written informed consent\n* Histologically confirmed primary infiltrating breast cancer with estrogen receptor expression \\\u003C1%, Progesterone receptor expression \\\u003C1%, and without overexpression and\u002For amplification of HER2 according to ASCO\u002FCAP 2013 guideline (locally assessed)\n* T2-3N0, T1-3N1 disease according to TNM-staging (8th edition, AJCC).\n* Nodal status must be examined by ultrasound and fine-needle aspiration or core biopsy in case of suspicious lymph nodes.\n* No evidence of distant metastases (Stage IV disease) on FDG-PET performed within 35 days of enrollment.\n* Age ≥18\n* WHO performance status ≤ 2\n* Visible breast tumor on contrast enhanced MRI (no minimal longest diameter required)\n* MRI breast must be performed within 35 days prior to registration\n* Patients with a history of autoimmune disease are eligible for the study per treating physician's discretion.\n* Laboratory requirements - within 21 days prior to enrollment:\n\n  * Adequate bone marrow function (ANC ≥1.5 x 109\u002Fl, platelets ≥100 x 109\u002Fl)\n  * Adequate hepatic function (ALT, AST and bilirubin ≤2.5 times upper limit of normal)\n  * Subjects with Gilbert's syndrome may have a total bilirubin ≥2.5 × the ULN range, if no evidence of biliary obstruction exists;\n  * Adequate renal function: creatinine clearance \\>50 ml\u002Fmin estimated using the Cockcroft-Gault equation, or based on a 24-hour urine collection measurement\n  * LVEF ≥50% measured by echocardiography\n* Women of childbearing potential and men must agree to remain abstinent (refrain from heterosexual intercourse) or use adequate contraceptive methods (failure rate of \\\u003C1% per year,) during treatment and for at least 6 months after the last dose of pembrolizumab. A woman is considered to be of childbearing potential if she is post-menarcheal, has not reached a postmenopausal state (≥12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and\u002For uterus). Examples of contraceptive methods with a failure rate of \\\u003C1% per year include bilateral tubal ligation, male sterilization, established, proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices (IUDs), and copper IUDs. Women who are not postmenopausal (≥12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative β-HCG serum or urine pregnancy test result.\n\nExclusion Criteria:\n\n* Concurrent breastfeeding\n* Concurrent contralateral or ipsilateral non-TNBC second primary infiltrating breast cancer. Contralateral or ipsilateral TNBC second primary infiltrating breast cancer or DCIS is allowed.\n* Concurrent anti-cancer treatment or another investigational drug\n* Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule\n* Patients who have a history of a second malignancy are eligible, provided the malignancy has been adequately treated, there is no ongoing treatment for the second malignancy, and overall principal investigator (PI) approval is obtained.\n* Has undergone excisional biopsy of the primary tumor, and\u002For axillary lymph node dissection prior to study treatment.\n* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.\n* History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's ability to cooperate with the requirements of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.",{"count":226,"type":22},54,[228],"PHASE2","Breast cancer is the most common malignancy among women worldwide. Triple-negative breast cancer (TNBC), defined by the lack of estrogen receptor, progesterone receptor, and HER2 expression, comprises approximately 15% of all breast cancers and is the most aggressive subtype, associated with a higher risk of early recurrence and death compared to other breast cancer subtypes. Neoadjuvant chemotherapy (NACT), administered before definitive surgery, is the standard of care for stage II-III TNBC (eTNBC), and pathological complete response (pCR), defined as the absence of invasive cancer in the breast and lymph nodes at surgery, following neoadjuvant systemic therapy, is strongly associated with improved survival in this population.\n\nIn the pivotal phase 3 KEYNOTE-522 study, the addition of Pembrolizumab (an immune checkpoint inhibitor (ICI), a PD-1 inhibitor) to NACT significantly improved both pCR rates and survival in patients with eTNBC , establishing a new standard of care for these patients. The KEYNOTE-522 regimen is a five-drug regimen administered in two distinct phases: in the first phase, Paclitaxel and Carboplatin are administered with Pembrolizumab for four cycles (TCa+P) and in the second phase, Adriamycin and Cyclophosphamide are administered with Pembrolizumab for an additional four cycles (AC+P). This regimen carries a high toxicity burden, particularly due to anthracyclines, which are associated with late cardiotoxicity and increased risk of therapy-related leukemias.\n\nMany patients, however, achieve an excellent response after only the first phase of treatment (paclitaxel-carboplatin + pembrolizumab), raising the question of whether treatment can be safely de-escalated in selected responders. Emerging evidence from the NeoPACT and NEO-N studies suggests that pCR rates of 55-58% can be achieved with taxane-carboplatin-pembrolizumab regimen, even in the absence of anthracyclines. Moreover, the recently published TRAIN-3 study in HER2+ breast cancer demonstrated that radiologic complete response on MRI (MRI-CR) strongly correlates with pCR in hormone receptor-negative disease, with 87% concordance.\n\nBuilding on this rationale, we propose a prospective, investigator-initiated, multicenter, phase II clinical trial in Israel to evaluate the feasibility and efficacy of MRI-guided de-escalation of NACT plus immunotherapy in patients with eTNBC. All enrolled patients will receive four cycles (12 weeks) of paclitaxel-carboplatin with pembrolizumab (TCa+P), followed by breast MRI to assess treatment response. Patients achieving MRI-CR will proceed directly to surgery, omitting the second phase of anthracycline-containing chemotherapy (AC+P). Patients with radiologic residual disease (MRI-RD) will complete the full KEYNOTE-522 regimen. Adjuvant therapy, including pembrolizumab continuation and\u002For additional chemotherapy, will be administered based on pathological findings and physician and patient discretion.\n\nThe primary endpoint is pCR rate among patients who achieve MRI-CR and undergo early surgery. The trial uses a Simon's two-stage optimal design and aims to test whether the observed pCR rate in MRI-CR patients exceeds the benchmark of 65% (based on KEYNOTE-522), with a target of 87% as suggested by TRAIN-3. Based on this approach, to reject the null hypothesis, a pathologic complete response (pCR) must be achieved in at least 22 of the 27 patients with MRI-CR who are referred to early surgery. Overall, Approximately 54 patients will be enrolled in the study to reach this goal. Key secondary endpoints include recurrence-free survival (RFS), overall survival (OS), and patient-reported quality of life (QoL). Patient-reported outcomes (PROs) will be collected longitudinally throughout the study to assess physical symptoms, psychological well-being, treatment-related toxicities, and functional recovery, helping to evaluate how treatment de-escalation impacts patient's experience.\n\nIn addition, the study will prospectively collect blood samples for circulating tumor DNA (ctDNA) analysis, creating a unique biorepository of biologic material for translational research. ctDNA dynamics will be evaluated as a complementary biomarker to MRI, enabling assessment of early treatment response, molecular residual disease, and mechanisms of resistance. Samples will be collected at multiple timepoints, before treatment, during therapy, and prior to surgery, providing a rich dataset for future genomic, epigenetic, and immune profiling studies.\n\nThis study represents an innovative, precision-driven approach to treatment de-escalation in eTNBC, with the potential to influence clinical practice and redefine the standard of care by identifying patients who can safely avoid anthracycline-based chemotherapy without compromising efficacy.",[231,232],"TNBC, Triple Negative Breast Cancer","Early Breast Cancer",[234,235,236],"TNBC","KEYNOTE-522","MRI","2025-12-24",{"date":239,"type":35},"2026-01-08",{"date":241,"type":35},"2025-11-11",{"date":243,"type":22},"2030-11-01",{"name":41,"class":42},{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":23,"phases":252,"briefSummary":253,"conditions":254,"keywords":256,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":4},"100607645","phase-2-a-phase-2-multicenter-open-label-trial-to-evaluate-efficacy-and-safety-of-subcutaneous-sc-mosunetuzumab-in-previously-untreated-low-tumor-burden-follicular-lymphoma-ltb-fl-100607645","NCT07191249","A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).","Inclusion Criteria:\n\n* at least 18 years old\n* Histologically confirmed classic FL (cFL) (according to WHO-HEAM4R classification)\n* Low tumor burden by GELF criteria\n* No prior therapy except surgery or radiotherapy for disease that was previously localized\n* Ann Arbor Stage III or IV disease\n* Bi-dimensionally measurable FDG-avid disease defined by at least one single node or tumor lesion \\> 1.5 cm assessed by CT scan and\u002For clinical examination\n* Adequate hematologic function defined as follows without growth factors or blood product transfusion within 14 days of first dose of study drug administration:\n\n  1. Hemoglobin, without transfusion, 9 g\u002FdL\n  2. ANC 1.0 109\u002FL\n  3. Platelet count 75 109\u002FL;\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2\n* Patient can understand and sign the Informed Consent Form (ICF), can communicate with the Investigator, can understand and comply with the requirements of the protocol\n\nExclusion Criteria:\n\n* 1\\. An active viral infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) defined by detectable viral DNA in the blood by PCR. Patients with HIV are eligible provided an undetectable viral load and a CD4 count \\> 200 cell\u002Fmcl\n* 2\\. Any of the following laboratory abnormalities:\n\n  1. Total Bilirubin or GGT or AST or ALT \\> 3 X ULN.\n  2. Creatinine Clearance calculated by Cockcroft and Gault Formula \\\u003C 40 ml\u002Fmin\n* Presence or history of CNS involvement by lymphoma\n* 4\\. Prior history of malignancies other than Lymphoma (except for Basal Cell or Squamous Cell Carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for ≥ 2 years\n* Contraindication to use Mosunetuzumabor known sensitivity or allergy\n* Pregnant or lactating females\n* 7\\. Female patients of childbearing potential who cannot or do not wish to use an effective method of contraception, during the study treatment and for 3 months thereafter",{"count":178,"type":22},[228],"This is a multi-center, open-label, interventional clinical trial designed to evaluate the efficacy and safety of subcutaneous (SC) Mosunetuzumab as a first-line immunotherapy in patients with low tumor burden follicular lymphoma (LTB-FL), defined by the absence of GELF criteria.\n\nEligible patients will undergo screening and, upon signing an Informed Consent Form, will receive their first dose of SC Mosunetuzumab.\n\nMosunetuzumab is administered via SC injection without the need for mandatory hospitalization. The first cycle lasts 21 days, followed by subsequent 28-day cycles. In Cycle 1, Mosunetuzumab is given on Day 1 (5 mg), Day 8 (45 mg), and Day 15 (45 mg). From Cycle 2 onward, a single 45 mg dose is administered on Day 1 of each cycle. Treatment continues for up to 8 cycles (approximately 6 months).\n\nPatients will be monitored for disease status according to standard clinical practice. After completing active treatment, they will enter a post-treatment follow-up phase. Premedication with dexamethasone (20 mg) is mandatory in Cycle 1 and optional in later cycles. Acetaminophen and diphenhydramine may also be administered.\n\nAll patients will continue study treatment as per the Schedule of Activities or until premature discontinuation. After treatment discontinuation, disease status assessments will occur approximately every 3 months for up to 24 months. During post-treatment follow-up, PET-CT scans for disease evaluation will be performed every 6 months, as applicable. Patients not under active follow-up will be contacted annually to collect data on disease status and survival.\n\nThroughout the trial, the following data will be collected (as applicable): demographics and baseline characteristics (including sex, age, race, height, and weight), medical history, details of initial diagnosis and treatment history, concomitant medications, adverse events (AEs), serious adverse events (SAEs), disease response, and survival status.",[255],"Follicular Lymphoma",[257,258],"Fullicular Lymphoma","Mosunetuzumab","2025-09-17",{"date":261,"type":35},"2025-09-24",{"date":263,"type":22},"2025-10-10",{"date":265,"type":22},"2029-03-01",{"name":41,"class":42},{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":23,"phases":277,"briefSummary":278,"conditions":279,"keywords":281,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":43},"100579829","tailored-one-anastomosis-gastric-bypass-100579829","NCT06829381","Tailored One Anastomosis Gastric Bypass","Tailoring One-Anastomosis Gastric Bypass Based on Total Small Bowel Length - A Randomized Controlled Trial","OAGB-TL","Inclusion Criteria:\n\n* Adults (≥18 years) undergoing OAGB\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years, pregnant women, or those lacking decision-making capacity Prior bariatric surgery Short bowel (\\\u003C450 cm)",{"count":276,"type":22},500,[25],"One Anastomosis Gastric Bypass (OAGB) is the most common metabolic and bariatric surgery (MBS) in Israel, recognized for its effectiveness in achieving sustainable weight loss and mitigating obesity-related diseases. The metabolic outcomes of OAGB are significantly influenced by the length of the biliopancreatic limb (BPL). The objective of this study is to determine whether tailoring the BPL length to the total small bowel length (TSBL) results in more effective weight loss compared to patients undergoing OAGB with a fixed BPL of 180 cm. Efficacy and safety of this approach will also be evaluated, ensuring it does not lead to long-term morbidity or negatively impact patients' quality of life.",[280],"Metabolic and Bariatric Surgery",[282,283,284,285],"one anastomosis gastric bypass","obesity","weight loss","tailoring","2025-07-21",{"date":288,"type":35},"2025-07-24",{"date":290,"type":35},"2025-01-29",{"date":292,"type":22},"2029-01-31",{"name":41,"class":42},{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":12,"sex":302,"minAge":303,"maxAge":176,"enrollmentInfo":304,"targetDuration":4,"studyType":23,"phases":306,"briefSummary":307,"conditions":308,"keywords":311,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":66},"100580580","phase-2-inhibiting-beta-adrenergic-and-cox-2-signaling-during-the-perioperative-period-to-reduce-ovarian-cancer-progression-100580580","NCT06839144","Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression","Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression: A Randomized Placebo-Controlled Clinical Trial","OC-POP-PT","Inclusion Criteria:\n\n* Age 20-85\n* ASA score 1-3 or ECOG Performance Status of 0 to 2\n* Patients with a suspected high-grade ovarian epithelial cancer based on imaging, clinical examination, CA125, and\u002For tumor biopsy\n* Patients planned for surgery for primary surgery, or interval debulking surgery for ovarian cancer\n* Signed informed consent form\n* Willing and able to comply with study procedures (physically and mentally)\n\nExclusion Criteria:\n\n* Patients who participate in another interventional study\n* Patients with known allergy to one or more of the study medications, or to any medication from the non-steroidal anti-inflammatory drug group or beta-blockers family\n* Patients treated chronically with any type of a beta-adrenergic blocker or a COX inhibitor, except use of Aspirin, which will be discontinued at least 7 days prior to surgery, and until 3 weeks post-surgery\n* Patients currently suffering from asthma (אסתמה פעילה בלבד), or required hospital admission or change in medical treatment for asthma within the past year\n* Patients with active peptic disease\n* Patients with a history of CVA\u002FTIA\n* Recent (within the last 5 years) or concurrent malignancies, with the exception of adequately treated in-situ carcinoma of the cervix or basal-cell carcinoma of the skin\n* Patients with renal failure, measured by creatinine level \\>1.5\n* Patients with significant liver dysfunction (known cirrhosis, Bilirubin level\\>2)\n* Patients with significant heart failure (NYHA functional class 3 or Higher)\n* Patients with bradycardia (heart rate of 50 or less) or second- or third-degree AV block\n* Patients with right-sided heart failure owing to pulmonary hypertension\n* Patients with chronic Digoxin treatment\n* Patients with Printzmetal's angina\n* Patients with significant diagnosed cardiomegaly\n* Patients suffering from sick sinus syndrome\n* Patients with peripheral vascular disease\n* Patients with current (unresected) pheochromocytoma\n* Pregnant women\n* Patients who are treated with immunosuppressive medications, including chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial drug\n* Patients with Immunodeficiency Disorders","FEMALE","20 Years",{"count":305,"type":22},60,[228],"This study investigates the impact of perioperative inhibition of beta-adrenergic and COX-2 signaling in ovarian cancer patients undergoing debulking surgery. The trial aims to assess the feasibility, safety, and biological effects of a combination of propranolol and etodolac in reducing cancer metastasis and improving immune responses.",[309,310],"Ovarian Cancer","Ovarian Cancer Metastatic Recurrent",[309,312,313,314,315,316,317,318,319,320],"Perioperative Intervention","Beta-Blockers","Propranolol","COX-2 Inhibitors","Etodolac","Psychoneuroimmunology","Stress and Cancer","Randomized Controlled Trial (RCT)","Biomarker Analysis","2025-07-08",{"date":323,"type":35},"2025-07-11",{"date":325,"type":35},"2025-03-12",{"date":327,"type":22},"2026-08-31",{"name":41,"class":42},{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":18,"minAge":336,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":23,"phases":339,"briefSummary":340,"conditions":341,"keywords":348,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":43},"100595306","plant-vs-animal-based-protein-sources-as-an-anabolic-and-metabolic-protective-options-for-so-in-older-adults-100595306","NCT07030738","Plant vs Animal-based Protein Sources as an Anabolic and Metabolic-protective Options for SO in Older Adults","Plant (Legumes) vs Animal-based (Meat) Protein Sources as an Anabolic and Metabolic-protective Options for Sarcopenic Obesity in Older Adults- A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 55 years or older.\n* Diagnosed with obesity.\n* At risk for sarcopenia, based on at least one of the following: Low score on the validated SARC-F-calf questionnaire (as suggested in prior studies). More than one comorbidity associated with sarcopenic obesity (e.g., diabetes, osteoporosis, cardiovascular disease, etc.). Polypharmacy: taking 8 or more prescribed medications. Evidence of strength or functional impairment, assessed using validated measurements at the baseline visit.\n\nExclusion Criteria:\n\n* Recent use of steroid agents within the past 6 months (replacement therapy is allowed).\n* Uncorrected hypothyroidism: TSH \\> 6 mIU\u002FL.\n* Diagnosis of malignancy within the past 5 years, except for non-melanoma skin cancer.\n* Chronic kidney disease (CKD) at stage \\>1 (due to protein restriction needs).\n* Recent (≤6 months) or unstable cardiovascular condition, or NYHA Class III or higher congestive heart failure.\n* Currently performing resistance training.\n* Currently undergoing nutritional therapy, have recently changed diet (\\\u003C1 month), or are enrolled in active weight-loss programs or therapies (including lifestyle and\u002For pharmacotherapy). Note: Patients stable on GLP-1 agonists or other pharmacotherapy are eligible.\n* Vegetarians\u002Fvegans, or individuals with aversion or allergy to all legumes or all red meat products.\n* Habitual consumption of more than 3 servings\u002Fweek of either legumes or red meat.\n* Other medical, psychiatric conditions, or lab abnormalities that may pose a risk to participation.","55 Years",{"count":338,"type":22},180,[25],"This study is testing how different types of protein - from red meat, legumes (like lentils and beans), or a mix of both - affect muscle strength, body composition, and metabolic health in older adults with obesity who are also at risk for sarcopenia (loss of muscle mass and function). Participants will follow a personalized weight loss diet with one high-protein meal each day that includes either red meat, legumes, or both, along with a home-based strength training program. The study will last three months and will include health assessments such as blood tests, muscle and fat measurements, and physical function tests. The goal is to find out which type of protein source is most helpful for improving strength, reducing body fat, and supporting healthy aging.",[342,343,344,345,346,347],"Sarcopenic Obesity","Obesity and Obesity-related Medical Conditions","Obesity (Body Mass Index >30 kg\u002Fm2)","Sarcopenia","Muscle Loss","Aging",[349,350,351,352,353,354,355,356,357,358,359,360,361,362,363,364,365,366],"Plant-based diet","Red meat","Legumes","Protein intake","Anabolic diet","Resistance training","Muscle mass","Body composition","Older adults","Functional status","Sarcopenic obesity","Hypocaloric diet","Leucine","Physical function","Metabolic health","Aging population","Nutrition intervention","Randomized controlled trial","2025-06-12",{"date":369,"type":35},"2025-06-22",{"date":371,"type":22},"2025-09",{"date":373,"type":22},"2026-06",{"name":41,"class":42},{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":23,"phases":384,"briefSummary":385,"conditions":386,"keywords":389,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":397,"leadSponsor":399,"locationsCount":43},"100590421","early-beta-blocker-administration-in-stemi-patients-with-scai-b-status-100590421","NCT06967194","Early Beta Blocker Administration in STEMI Patients With SCAI B Status","Early Beta-Blocker Administration in Patients With ST Segment Elevation Myocardial Infraction and SCAI B Status","Inclusion Criteria:\n\n* Diagnosis of ST-segment elevation myocardial infarction (STEMI) confirmed by ECG, clinical signs, and coronary catheterization.\n* Post-catheterization patients classified as SCAI B upon admission to the unit, defined by the presence of tachycardia and\u002For hypotension without signs of hypoperfusion (i.e., normal lactate levels, normal capillary refill, preserved mental status, and adequate urine output \\>0.5 mL\u002Fkg\u002Fhour).\n* Age 18 years or older.\n* Mentally competent to provide informed consent, understand the study procedures, and comply with medical recommendations.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Inability to provide informed consent.\n* Evidence of pulmonary edema.\n* Bradycardia (heart rate \\\u003C60 beats per minute).\n* PR interval \\>240 milliseconds.\n* Second- or third-degree atrioventricular (AV) block.\n* Active asthma.\n* Known hypersensitivity to metoprolol.",{"count":383,"type":22},200,[25],"This study is looking at how a medication called beta-blockers (metoprolol) affects patients with a heart attack (STEMI) who are in the cardiac intensive care unit.\n\nWhen patients are admitted to the unit, they will be randomly placed in one of two groups. One group will get the metoprolol medication, and the other will receive a placebo (a harmless pill that looks like the real medication). All other treatments will be the same for both groups.\n\nDuring the study, which is 72 hours long, patients will be monitored for blood pressure, heart rate, and lactate levels alterations.\n\nThe main goal is to see if the medication helps improve patients condition or prevent it from getting worse. patients safety is a top priority, and if needed, the doctors can stop the study at any time if there are concerns.",[387,388],"ST Segment Elevation Myocardial Infarction (STEMI)","Cardiogenic Shock Post Myocardial Infarction",[390,391,392],"acute MI","stemi","beta blockers","2025-05-21",{"date":395,"type":35},"2025-05-28",{"date":393,"type":35},{"date":398,"type":22},"2027-06",{"name":41,"class":42},{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":407,"enrollmentInfo":408,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":410,"conditions":411,"keywords":414,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":43},"100590396","evaluation-of-fentanyl-transdermal-patch-absorption-in-hemodynamically-unstable-icu-patients-100590396","NCT06966869","Evaluation of Fentanyl Transdermal Patch Absorption in Hemodynamically Unstable ICU Patients.","Pharmacokinetic Study Evaluating the Absorption of Fentanyl From Transdermal Patches in Hemodynamically Unstable Versus Stable Patients Admitted to the Surgical Intensive Care Unit.","Inclusion Criteria:\n\n* Adults aged 18-70 years.\n* Male or female patients.\n* Admitted to the surgical intensive care unit (ICU).\n* Indications for pain management using fentanyl.\n\nExclusion Criteria:\n\n* No clinical indication for fentanyl analgesia (e.g., pain well controlled with non-opioid medications).\n* Known allergy or hypersensitivity to fentanyl.\n* Contraindications to fentanyl (e.g., severe constipation, hepatic failure)\n* Patients infected with multidrug-resistant organisms require high-level isolation (biosafety level 2 or higher).\n* Hemodynamically very unstable patients requiring \\>20 drops\u002Fhour of norepinephrine (4 mg\u002F50 mL), with or without vasopressin support.","70 Years",{"count":409,"type":22},40,"This study investigates how well fentanyl is absorbed through the skin when delivered via a transdermal patch in critically ill surgical ICU patients. It compares hemodynamically stable patients with unstable patients who require vasopressors to maintain adequate blood pressure. Fentanyl blood levels will be measured over time to assess whether absorption is impaired in unstable patients. The goal is to determine whether transdermal fentanyl is a viable option for pain management in resource-limited ICUs or in situations where intravenous fentanyl is unavailable.",[412,413],"Pain Management","Critical Illness",[415,416,417],"Transdermal fentanyl","Critical illness","Hemodynamic instability","2025-05-04",{"date":420,"type":35},"2025-05-13",{"date":422,"type":35},"2025-04-22",{"date":424,"type":22},"2028-04-22",{"name":41,"class":42},{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":435,"conditions":436,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":4},"100584401","multiple-myeloma-is-a-hematologic-malignancy-characterized-by-the-accumulation-of-malignant-plasma-cells-in-the-bone-marrow-despite-advances-in-treatment-many-patients-experience-disease-relapse-bispecific-antibodies-offer-an-innovative-therapeutic-approach-but-approximately-30-40-of-patients-100584401","NCT06888856","Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients","Observational Study on Genomic and Proteomic Mechanisms in Multiple Myeloma Patients Treated With Bispecific Antibodies and CAR-T Therapies","MMOMICS","Inclusion Criteria:\n\nDiagnosed with multiple myeloma Candidate for BisAb, CAR-T, or other myeloma therapy Mentally competent and able to sign informed consent\n\nExclusion Criteria:\n\nUnable to undergo bone marrow sampling Pregnant women Minors (\\\u003C18), incapacitated, or legally incompetent",{"count":383,"type":22},"This prospective, non-interventional study aims to characterize the molecular and cellular mechanisms underlying the response and resistance of multiple myeloma (MM) patients to bispecific antibodies (BisAb) and CAR-T therapies. Conducted at the Tel Aviv Sourasky Medical Center, the study will enroll up to 200 MM patients aged 18 and older, who are candidates for BisAb, CAR-T, or other MM treatments. Bone marrow (4-6 mL) and peripheral blood (15-20 mL) samples will be collected before treatment and at predefined intervals post-treatment, including at disease relapse\u002Fprogression. The study will analyze plasma cells and the tumor microenvironment (TME) using techniques such as flow cytometry (FACS), single-cell RNA sequencing, genomic DNA sequencing, and ELISA to assess soluble BCMA levels. Key objectives include identifying genetic and protein signatures predictive of treatment response, evaluating specific drug binding, and analyzing interactions between plasma cells and immune cells (e.g., T cells). Samples will be processed and stored at the study site, with data coded to ensure patient confidentiality. Results will inform personalized treatment strategies for MM patients. The study duration includes 5 years for sample collection, 1 year for data analysis, and up to 20 years for sample storage.",[437],"Multiple Myeloma (MM)","2025-03-17",{"date":440,"type":35},"2025-03-21",{"date":442,"type":22},"2025-03-19",{"date":444,"type":22},"2031-03-03",{"name":41,"class":42},{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":450,"acronym":451,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":407,"enrollmentInfo":453,"targetDuration":4,"studyType":23,"phases":455,"briefSummary":456,"conditions":457,"keywords":459,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":43},"100574844","the-effect-of-a-mediterranean-diet-on-quality-of-life-in-multiple-sclerosis-patients-100574844","NCT06764563","The Effect of a Mediterranean Diet on Quality of Life in Multiple Sclerosis Patients","Mediet4MS","Inclusion Criteria:\n\n* Confirmed MS based on 2017 Mcdonald criteria, with stable medication regimen in the previous six months.\n\nExclusion Criteria:\n\n* Pregnancy or lactating\n* People with a lack of judgment\n* Serum creatinine ≥2 mg\u002FdL(177 μmol per liter) or more\n* Patients who had gastrointestinal problems that would prevent them from following any of the test diets\n* Patients who had liver dysfunction (an increase by a factor of at least two above the upper limit of normal in alanine aminotransferase and aspartate aminotransferase levels)\n* Active cancer or chemotherapy treatment in the last three years.",{"count":454,"type":22},140,[25],"The role of dietary interventions in improving symptoms of multiple sclerosis (MS) is of high interest amongst patients and researchers, but data supporting this evidence are limited. Current evidence indicates that A higher Expanded Disability Status Scale (EDSS) score correlates with poor diet quality in patients with MS. Moreover, even though disease-modifying therapies (DMT) improve disease course and prognosis, MS patients report a lower quality of life (QoL) than people without illness. The Mediterranean diet (Med-Diet) is beneficial in preventing cardiovascular comorbidities, and outcomes of a decrease in inflammation processes are evident. Recent studies suggest that the Med-Diet might positively affect MS QoL, However, empirical evidence remains unclear, limiting the possibility of evidence-based nutritional recommendations. In the current study, we aim to investigate the effect of the Mediterranean diet on the quality of life of patients with MS.\n\nMethods:\n\nRandomized controlled trial among MS patients aged 18-70. The participants will be randomly assigned to two 1:1 ratio groups: The med-diet group and the control group (no intervention). The intervention will be carried out for six months with subsequent six-months follow-up.\n\nNine nutrition sessions will be delivered to the intervention group by an expert registered clinical dietitian. Data will be collected at baseline, three months, six months, and 12 months, including the following: Demographic, Anthropometric measurements, Blood tests of complete blood count, chemistry, levels of vitamins D, and B12, CRP, neurofilaments light chain (NfL), Grip strength, Biochemical analysis for fatty acid composition in membranes of red blood cells (RBC) and HPLC analysis of carotenoid concentration. Patients will complete questionnaires for multiple sclerosis quality of life-54 (MSQoL-54), Patient Health Questionnaire (PHQ-9), Fatigue Severity Scale Questionnaire (FSS) and will undergo clinical evaluation for expanded disability status scales (EDSS) and Symbol Digit Modalities Test (SDMT). Dietary analysis and Med-Diet adherence will be validated by the Israeli Mediterranean diet screener (I-MEDAS) and by Food diaries.\n\nCalculated sample size: To achieve a mean difference of 10 points in the MSQoL-54 questionnaire and 80% power, a sample of 77 participants per group is needed. Considering a 5% drop-off, 81 participants per group are needed, and overall, 162 participants.\n\nExpected results: this study will highlight the effect of the Med-Diet dietary pattern on MS quality of life, MS symptoms, and its underlying mechanism, to enable evidence-based nutritional recommendations for MS patients\n\nImportance to Medicine: MS patients suffer from a decrease in QoL. Hence, physicians, researchers, and patients seek nutritional approaches that may improve their condition. If proven beneficial, The Med diet, a dietary approach that has been proven to reduce the risk for major comorbidities and that can be sustained throughout life, has the potential to improve the condition of MS patients in crucial lifestyle aspects.",[458],"Multiple Sclerosis",[460,461,462],"multiple sclerosis","mediterranean diet","quality of life","2025-02-24",{"date":465,"type":35},"2025-02-25",{"date":467,"type":35},"2025-02-01",{"date":469,"type":22},"2028-01-01",{"name":41,"class":42},{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":479,"targetDuration":481,"studyType":129,"phases":4,"briefSummary":482,"conditions":483,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":43},"100555991","freezing-of-gait---clinical-outcomes-assessment-100555991","NCT06519279","Freezing of Gait - Clinical Outcomes Assessment","An International Multimodal Protocol for Assessing Freezing of Gait in Individuals Living with Parkinson's Disease","FOG-COA","Inclusion Criteria:\n\n1. Diagnosis of idiopathic Parkinson's disease (PD) made by a neurologist according to the Movement Disorders Society guidelines;\n2. Able to walk independently for a distance of 10 meters, without walking aid;\n3. Absence of a Deep Brain Stimulator;\n4. Stable PD treatment in the 4 weeks prior to participation that is not expected to change in the course of the study.\n5. For patients with FOG: a score of ≥ 1 on the New Freezing Of Gait Questionnaire (NFOG-Q).\n\nExclusion Criteria:\n\n1. Occurrence of any of the following within 3 months prior to informed consent: myocardial infarction, hospitalization for unstable angina, stroke, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), implantation of a cardiac resynchronization therapy device (CRTD), active treatment for cancer or other malignant disease, uncontrolled congestive heart disease (NYHA class \\>3), acute psychosis or major psychiatric disorders or continued substance abuse, other neurological (than PD) or orthopaedic impairment that significantly impacts on gait.\n2. Unwilling to temporarily delay the morning anti-Parkinsonian medication.\n3. Preganacy and",{"count":480,"type":22},20,"1 Month","To develop a reliable and accurate clinician-reported outcome (ClinRO) measure (against a new and precise definition) and patient reported outcome (PRO) for use by clinicians and researchers to quantify the severity of Freezing of Gait (FOG).",[484],"PD - Parkinson's Disease","2025-01-23",{"date":487,"type":35},"2025-01-28",{"date":489,"type":35},"2024-10-01",{"date":491,"type":22},"2025-12",{"name":41,"class":42},{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":499,"eligibilityCriteria":500,"healthyVolunteers":201,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":501,"targetDuration":502,"studyType":129,"phases":4,"briefSummary":503,"conditions":504,"keywords":507,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":43},"100566557","cancerend24-screening-as-an-aid-to-the-clinician-for-the-diagnosis-of-cancer-100566557","NCT06656728","CancerenD24 Screening as an Aid to the Clinician for the Diagnosis of Cancer","Clinical Validation Of A Diagnostic Cancerend24 Screening As An Aid To The Clinician For The Diagnosis Of Cancer In Healthy Subjects Attending The ICPC","CancerenD24","Inclusion Criteria:\n\n1. Completion of all medical exams and questionnaires including cancer diagnoses, demographic data and other epidemiologic information\n2. Willing and able to sign an informed consent\n3. Age ≥40 years\n\nExclusion Criteria:\n\n1. Age \\\u003C 40 years\n2. Pregnancy or breastfeeding\n3. Any type of fever\n4. Any cancer active at study entry or up to 5 years prior to study entry\n5. Polyposis syndromes\n6. Inflammatory bowel disease\n7. Unwilling or unable to provide informed consent",{"count":204,"type":22},"36 Months","The purpose of the researchers is to test whether the CancerenD24 index, an algorithm based on the quantitative value of CD24, CD11b, clinical and laboratory characteristics, developed in the laboratory can help in the early detection of a malignant disease in a population of healthy subjects.",[505,506],"Cancer","Early Detection of Cancer",[505,508,509,499,510,511,512],"Early detection","Venous blood sample","CD24","CD11b","Malignant disease","2024-10-23",{"date":515,"type":35},"2024-10-24",{"date":517,"type":35},"2024-09-03",{"date":519,"type":22},"2027-09",{"name":41,"class":42},{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":4,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":528,"targetDuration":4,"studyType":23,"phases":530,"briefSummary":532,"conditions":533,"keywords":535,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":43},"100562254","phase-4-mealtime-or-post-meal-dosing-of-urli-in-medtronic-780g-hybrid-closed-loop-system-100562254","NCT06600776","Mealtime or Post-meal Dosing of URLi in Medtronic 780G Hybrid Closed Loop System","A Pilot Study Comparing the Efficacy of Dosing Ultra Rapid Insulin Lispro in a Medtronic 780G Hybrid Closed Loop System at Mealtime or Postmeal","Inclusion Criteria:\n\nParticipants must be 18 years of age or older (inclusive).\n\nDiagnosed with Type 1 Diabetes Mellitus (T1DM).\n\nAlready using the MiniMed 780G hybrid closed-loop system with Ultra Rapid Lispro Insulin (URLi) for at least 2 months prior to study enrollment.\n\nAble and willing to provide informed consent electronically.\n\nWilling and able to comply with the scheduled visits and other study procedures, including remote monitoring and completing questionnaires.\n\nExclusion Criteria:\n\nParticipants with a medical history of untreated active proliferative retinopathy.\n\nNote: Subjects with non-proliferative retinopathy may be included. Subjects with treated proliferative retinopathy may be included based on the investigator's clinical judgment.\n\nSevere acute or chronic medical or psychiatric conditions or laboratory abnormalities that may increase the risk associated with study participation or interfere with the interpretation of study results, as judged by the investigator.",{"count":529,"type":22},50,[531],"PHASE4","This is a pilot study to compare premeal to postmeal dosing of ultra rapid lispro insulin (URLi) used in a MiniMed 780G system hybrid closed loop system. Subjects with type 1 diabetes mellitus (T1DM) already using a 780G hybrid closed loop system with URLi will be included. After signing a remote digital informed consent, a baseline record of the MiniMed 780G system will be downloaded from the Medtronic digital platform (Carelink system \\[1\\]) and subjects will be asked to fill an online questionnaire regarding their time of insulin dosing preferences and a 3-day online food diary \\[2\\]. During the intervention period subjects will be asked to provide a bolus dose of insulin only at the end of meals for up to 4 weeks. During the last week of the intervention period, subjects will be asked to fill out a 3-day online food diary \\[2\\]. At the end of the intervention period- a Carelink report \\[1\\] will be collected remotely and subjects will be asked to fill again the online questionnaire regarding their time of dosing preferences.\n\n1. Primary Objective: To assess the efficacy of premeal dosing to post-meal dosing on parameters of glycemic control as obtained from continuous glucose monitoring.\n2. Secondary Objective: To assess patient dosing preferences and the effect of premeal dosing vs. post-meal dosing on patient reported outcomes\n\nRef:\n\n1. carelink.medtronic.eu\n2. NutRatio.com.",[534],"Type 1 Diabetes (T1D)",[536,537,538,539,540,541,542,543,544,545,546,547,548,549],"Automated Insulin Delivery","Continuous Glucose Monitoring (CGM)","Glycemic Control","Hybrid Closed Loop System","Insulin Bolus","Lyumjev","Mealtime Dosing","Medtronic 780G","Patient Preferences","Postmeal Dosing","Postprandial Glycemia","Time in Range (TIR)","Type 1 Diabetes Mellitus (T1DM)","Ultra Rapid Lispro Insulin (URLi)","2024-09-22",{"date":552,"type":35},"2024-09-24",{"date":554,"type":22},"2024-10-06",{"date":556,"type":22},"2025-10-21",{"name":41,"class":42},{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":562,"acronym":563,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":18,"minAge":565,"maxAge":566,"enrollmentInfo":567,"targetDuration":4,"studyType":23,"phases":569,"briefSummary":570,"conditions":571,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":579,"locationsCount":4},"100560769","home-transcranial-direct-current-stimulation-for-motoric-cognitive-risk-syndrome-100560769","NCT06581458","Home Transcranial Direct-Current Stimulation for Motoric Cognitive Risk Syndrome","HometDCS","Inclusion Criteria:\n\n* Age 65-90\n* Cognitive complaints\n\n  * A positive answer to the question \"Do you feel you have more problems than most people?\"\n  * A negative answer to the question \"Is your thinking as clear and sharp as it was before?\"\n* Slow walking - one standard deviation below the average for age and gender (under age 75: men less than 101.9 cm\u002Fs, women less than 97.4 cm\u002Fs. Over or equal to age 75: men less than 85.3 s) m\u002Fs women less than 76.7 cm\u002Fs)\n* No significant disability\n\n  * There is the ability to walk without support on a walking carpet\n  * A result below 9 in the Functional Activities Questionnaire index\n* Identification as qualified\n* Identification as willing and able to operate a tDCS device or have a partner who is able to operate the device during home use. According to the criteria:\n\n  * Inclusion: selected by the patient, over the age of 21, with basic computer skills and available throughout the study period\n  * Exclusion: MOCA score lower than or equal to 26. Presents insufficient understanding, poor vision, severe joint problems in the hands, deformity pain or other conditions that may interfere with the successful operation of the tDCS\n* Has access to a reliable wireless internet network (WiFi) at the patient's home\n\nExclusion Criteria:\n\n* Less than eight years of study\n* dementia\n\n  * According to the clinical definition clinical dementia rationing (CDR) score 1 or higher\n  * Previous diagnosis\n  * Performance in the range indicating dementia in the neuropsychological test bettery (lower than 2 standard deviations below the age- and sex-matched average)\n* IQ is low or equal to 85 in the WTAR test. without a background of mental disability\n* Current diagnosis of major psychiatric disorders (schizophrenia, bipolar, major depression)\n* Evidence of moderate to severe symptoms of depression. A score high or equal to 9 on the 15 item geriatric depression scale\n* History of head injury that led to prolonged loss of consciousness\n* History of palpitations of unknown origin that may indicate convulsions\n* History of convulsions, diagnosis of epilepsy in the patient or in most of the first degree family. Except for a case of a single seizure of benign etiology determined by a neurologist\n* Hospitalization during the last three months following an acute illness or musculoskeletal injury with a significant impact on walking or stability\n* An unbalanced medical condition that can worsen following convulsive stimulation (cardiac malformation, cardiac arrhythmias, asthma, etc.)\n* Substance use disorders during the last six months\n* A wig or hair design that prevents contact of the electrodes with the scalp or interferes with the administration of the stimulation\n* Chronic vertigo\n* A cardiac event within the last six months\n* Active cancer treated with chemotherapy or radiation\n* blindness\n* Visual hallucinations (according to history or self-report)\n* There are contraindications for MRI or tDCS as defined by the International Federation for Clinical Neurophysiology\n\n  * Includes unprovoked convulsions during the last 2 years\n  * Danger of finding ferromagnetic objects in the body, self-reporting of medical implants in the body (DBS, deep brain stimulation, drug delivery pump, cochlear implant, pacemaker)\n  * Inventions active dermatological condition\n* History of behavior disorders in REM sleep, sometimes an early sign of Parkinson's disease\n* Medications and medical history will be examined by a clinician and a decision regarding entry into the study will be based on medical history, current medication dosage and medication change before or during the treatment as well as combination with other active CNS medications.","65 Years","90 Years",{"count":568,"type":22},64,[25],"1. To examine the effect of a two-week tDCS intervention of 3 months of continued tDCS intervention versus 3 months of receiving a placebo treatment (dummy). On the costs of performing an action task (dual task cost) walking speed, cognitive measures and motor function.\n2. To examine whether the effects of tDCS build up over time by creating a delayed start mechanism in the intervention (delayed-start design)\n3. Examining mechanical and neuroplastic effects of tDCS intervention\n4. To examine the response to tDCS over time",[572],"Motoric Cognitive Risk Syndrome","2024-08-26",{"date":517,"type":35},{"date":576,"type":22},"2024-09",{"date":578,"type":22},"2026-09",{"name":41,"class":42},{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":584,"acronym":585,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":18,"minAge":587,"maxAge":566,"enrollmentInfo":588,"targetDuration":4,"studyType":23,"phases":590,"briefSummary":591,"conditions":592,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":598,"leadSponsor":599,"locationsCount":4},"100557499","steps-against-the-burden-of-parkinsons-disease---stepup-100557499","NCT06538909","Steps Against the Burden of Parkinson's Disease - StepuP","StepuP","Inclusion Criteria:\n\nSpecific criteria for Parkinson's disease - PD\n\n* Diagnosis of Parkinson's disease according to the MDS World Movement Disorders Society criteria Disease severity H\\&Y I-III\n* Score section 3.10 (ability to walk) MDS-UPDRS 3.10 ≥ 1\n* MoCA cognitive assessment \\> 15\n* Stable cardiovascular condition, ability to perform aerobic activity at low to moderate intensity\n* Without orthopedic diseases and other diseases that affect the quality of walking, at the decision of the researcher.\n\nExclusion Criteria:\n\n* Moderate or severe depression (BDI-II ≥18)\n* Orthopedic diseases and other diseases that affect the quality of walking, at the decision of the researcher","25 Years",{"count":589,"type":22},21,[25],"The goals of our StepuP project are:\n\n1. To understand the kinematic and neural mechanisms underlying walking improvements due to treadmill training with and without VR-enabled gait adaptations in people with PD;\n2. To assess to what extent improvements in walking due to treadmill training, as measured in the laboratory, transfer to improvements in daily life mobility;\n3. To understand the mechanisms underlying the transfer from improvements in walking to improvements in mobility in daily life in people with PD;\n4. To understand for whom treadmill training improves walking characteristics in the laboratory and for whom it does not, and to understand for whom treadmill training improves mobility in daily life and for whom it does not.",[593],"Parkinson Disease","2024-08-05",{"date":596,"type":35},"2024-08-06",{"date":576,"type":22},{"date":491,"type":22},{"name":41,"class":42},{"id":601,"slug":602,"hasResults":12,"nctId":603,"briefTitle":604,"officialTitle":604,"acronym":4,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":606,"targetDuration":4,"studyType":23,"phases":608,"briefSummary":609,"conditions":610,"keywords":615,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":43},"100555310","phase-2-early-interferon-beta-treatment-for-west-nile-virus-infection-100555310","NCT06510426","Early Interferon-beta Treatment for West-Nile Virus Infection","Diagnosis of WNV infection will be based on the following:\n\n1. Patients with clinical presentation suspected as compatible with WNV infection, with symptoms including elevated fever, headache or flaccid paralysis or fever with encephalopathy.\n\n   And:\n2. Positive anti-WNV IgM serology \u002F WNV PCR from either serum, urine or CSF.\n\nInclusion criteria:\n\nWe aim to focus on three patients' populations:\n\n1. Patients older than 70 years of age, who are at higher risk for the presence of neutralizing anti-Type I IFN auto-antibodies, and therefore at higher risk for developing severe neuroinvasive disease. Only patients who fulfill the diagnostic criteria above will be included.\n2. Patients presenting with neuroinvasive WNV disease, including either flaccid paralysis or encephalitis, independent of their age, excluding a presentation consistent with isolated aseptic meningitis (headache, fever, 6th nerve palsy). Only patients who fulfill the diagnostic criteria above will be included.\n3. Immunocompromised patients at any age. Immunocompromised patients will be defined as patients with hematologic malignancy (treated or untreated); chemotherapy within previous 4 weeks, stem cell transplant recipient or solid organ transplant recipient; use of any immunosuppressant drug including prednisone greater than or equal to 20 mg\u002Fday within the previous 4 weeks; primary \u002F acquired immunodeficiency disorder. Only patients who fulfill the diagnostic criteria above will be included.\n\nExclusion Criteria:\n\n1. Patients younger than 18 years old.\n2. Pregnant women.\n3. Contraindication for the administration of the drug: Hypersensitivity to natural or recombinant interferon beta, and decompensated liver disease.\n4. A patient with neuroinvasive disease showing consistent spontaneous improvement over a period of \\> 2 days and mRS of below 4.\n5. More than 8 days from onset of neurological symptoms in immunocompetent patients and more than 10 days in immunocompromised patients. This time frame will be renewed if a patient with flaccid paralysis develops new onset encephalitis.\n6. Patients who are receiving active chemotherapy treatment or suffer concurrent severe viral infection.",{"count":607,"type":22},100,[228],"West Nile virus (WNV) is a mosquito-borne virus which in majority of cases causes only self-limited disease.\n\nDespite that, in minority of cases (\\~0.5%) it can infect the brain and cause severe and even life-threatening disease (neuroinvasive disease).\n\nRecent study has shown that up to 40% of WNV patients who develop neuroinvasive disease, have antibodies against Interferons (anti-Type I interferon autoantibodies), which neutralizes interferons, and could explain the development of severe disease.\n\nThe investigators therefore assume that early treatment with interferon beta (the type of interferon against which most patients do not have neutralizing antibodies) could prevent the development of severe neuroinvasive WNV disease.",[611,612,613,614],"West Nile Virus","West Nile Fever Encephalitis","West Nile Fever Myelitis","West Nile Fever With Other Complications",[611,616,617,618,619],"WNV","Encephalitis","Flaccid paralysis","WNV neuroinvasive disease","2024-07-20",{"date":622,"type":35},"2024-07-23",{"date":624,"type":35},"2024-07-14",{"date":626,"type":22},"2025-12-31",{"name":41,"class":42},{"id":629,"slug":630,"hasResults":12,"nctId":631,"briefTitle":632,"officialTitle":633,"acronym":4,"eligibilityCriteria":634,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":407,"enrollmentInfo":635,"targetDuration":4,"studyType":23,"phases":636,"briefSummary":637,"conditions":638,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":640,"lastUpdatePostDateStruct":641,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":646,"locationsCount":43},"100464587","phase-1-auto-fecal-microbial-transplant-post-helicobacter-pylori-antibiotic-therapy-100464587","NCT05329636","Auto Fecal Microbial Transplant Post Helicobacter Pylori Antibiotic Therapy","Fecal Auto-transplantation for Enteric Microbial Rehabilitation Post 14 Day Antibiotics Therapy Against Helicobacter Pylori Infection","Inclusion Criteria:\n\n* Age 18-70 years old\n* Positive H. pylori on either breath test or gastric biopsy\n* Patient is intended to receive antibiotics therapy for H. pylori eradication\n\nExclusion Criteria:\n\n* Severe systemic disease that may impact the microbiome. For example: heart disease, type two diabetes, chronic liver or kidney failure\n* Antibiotics therapy during the prior 2 months to enrollment\n* Planned to receive antibiotics within the upcoming 2 months (surgery etc) for reasons other than H. Pylori\n* Inability to complete the study protocol (swallow capsules or to hold enema content for at least 15 minutes)\n* Pregnancy\n* Inability to give informed consent",{"count":178,"type":22},[156,228],"Current guidelines mandate Helicobacter pylori (H. Pylori) eradication with 2-3 antibiotics for 14 days ,This may result in multiple side effects and in eradication of important bacterial species to human health, exposing humans to multiple disease conditions.\n\nPreservation of fecal microbiome prior to antibiotic therapy and auto-transplantation of the microbes post H. pylori eradication, will enable avoiding eradication of beneficial microbial populations and perhaps protect from consequent disease conditions.",[639],"Helicobacter Pylori Infection","2024-07-03",{"date":642,"type":35},"2024-07-08",{"date":644,"type":35},"2018-09-26",{"date":37,"type":22},{"name":41,"class":42},{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":651,"acronym":652,"eligibilityCriteria":653,"healthyVolunteers":201,"sex":18,"minAge":654,"maxAge":4,"enrollmentInfo":655,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":657,"conditions":658,"keywords":660,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":664,"lastUpdatePostDateStruct":665,"startDateStruct":667,"completionDateStruct":669,"leadSponsor":671,"locationsCount":43},"100496629","a-natural-history-study-of-preclinical-genetic-creutzfeldt-jakob-disease-cjd-100496629","NCT05746715","A Natural History Study of Preclinical Genetic Creutzfeldt-Jakob Disease (CJD)","NHS_CJD","Inclusion Criteria:\n\n* First--degree relative of an E200K gCJD patient.\n* Age 50 years or older at baseline.\n* Willingness to undergo genetic testing.\n* Ability to provide written informed consent under GCP, ICH, and local regulations.\n* Willingness and ability to comply with scheduled visits, required study procedures, and laboratory tests.\n\nExclusion Criteria:\n\n* a clinical diagnosis of CJD\n\n  * Any other medical or psychiatric condition or laboratory abnormality, which in the opinion of the investigator might preclude participation.\n  * Previously obtained MRI scan with evidence of clinically significant neurological disorder other than CJD.\n  * Current anticoagulant treatment (e.g Non-vitamin K Antagonist Oral Anticoagulants (NOACs), Warfarin, Low Molecular weight Heparin) that might preclude safe completion of LP.\n  * Conditions that preclude the safe performance of LP, such as severe lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia.\n  * Conditions that preclude the safe performance of MRI scannings such as subjects who have a pacemaker, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin, or body, or any other known contra-indication for MRI.\n  * Active malignant disease.","50 Years",{"count":656,"type":22},126,"Creutzfeldt-Jakob Disease (CJD) is the most common prion disease in humans causing a rapidly progressive neurological decline and dementia and is invariably fatal. The familial forms (genetic CJD, gCJD) are caused by mutations in the PRNP gene encoding for the prion protein (PrP). In Israel, there is a large cluster of gCJD cases, carriers of an E200K mutation in the PRNP gene, and therefore the largest population of at-risk individuals in the world. The mutation is not necessarily sufficient for the formation and accumulation of the pathological prion protein (PrPsc), suggesting that other, genetic and non-genetic factors affect the age at symptoms onset. Here we present the protocol of a cross-sectional and longitudinal natural history study of gCJD patients and first-degree relatives of gCJD patients, aiming to identify biological markers of preclinical CJD and risk factors for phenoconversion.\n\nThe study includes two groups: Patients diagnosed with gCJD, and first-degree healthy relatives (both carriers and non-carriers of the E200K mutation in the PRNP gene) of patients diagnosed with gCJD. At baseline, and at the end of every year (for 4 years), healthy participants are invited for an \"in-depth\" visit, which includes a clinical evaluation, blood and urine collection, gait assessment, brain MRI, lumbar puncture, and Polysomnography sleep lab (PSG). At 6 months from baseline, and then halfway through each year, participants are invited for a \"brief\" visit, which includes a clinical evaluation, short cognitive assessment, and blood and urine collection. gCJD patients will be invited for one \"in-depth\" visit, similar to the baseline visit of healthy relatives.",[659],"Creutzfeldt-Jakob Disease (CJD)",[661,662,663],"Creutzfeldt-Jakob Disease","Prion disease","E200K mutation","2023-02-27",{"date":666,"type":35},"2023-02-28",{"date":668,"type":35},"2022-06-01",{"date":670,"type":22},"2029-05-30",{"name":41,"class":42},""]